Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2006;37:2830-2836
Published online before print September 28, 2006, doi: 10.1161/01.STR.0000245088.60282.22
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/11/2830    most recent
01.STR.0000245088.60282.22v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, Y.
Right arrow Articles by Watanabe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cui, Y.
Right arrow Articles by Watanabe, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Nuclear Scans
Related Collections
Right arrow Animal models of human disease
Right arrow Brain Circulation and Metabolism
Right arrow PET and SPECT
Right arrow Neuroprotectors

(Stroke. 2006;37:2830.)
© 2006 American Heart Association, Inc.


Original Contributions

Neuroprotection by a Central Nervous System–Type Prostacyclin Receptor Ligand Demonstrated in Monkeys Subjected to Middle Cerebral Artery Occlusion and Reperfusion

A Positron Emission Tomography Study

Yilong Cui, PhD; Hiroyuki Takamatsu, PhD; Takeharu Kakiuchi, PhD; Hiroyuki Ohba, PhD; Yosky Kataoka, MD, PhD; Chihiro Yokoyama, MD, PhD; Hirotaka Onoe, PhD; Yumiko Watanabe, PhD; Takamitsu Hosoya, PhD; Masaaki Suzuki, PhD; Ryoji Noyori, PhD; Hideo Tsukada, PhD Yasuyoshi Watanabe, MD, PhD

From Molecular Imaging Research Program (Y.C., Y.K., C.Y., H.O., Y.W., M.S., Y.W.), Frontier Research System, Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan; Department of Physiology (Y.C., Y.K., Y.W., Y.W.), Osaka City University Graduate School of Medicine, Osaka, Japan; Hamamatsu Pharma Research, Inc (H.T.), Hamamatsu, Shizuoka, Japan; Central Research Laboratory (T.K., H.O., H.T.), Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan; Department of Biomolecular Science (T.H., M.S.), Faculty of Engineering, Gifu University, Gifu, Japan; Department of Chemistry and Molecular Chirality Research Unit (R.N.), Nagoya University, Nagoya, Aichi, Japan.

Correspondence to Yasuyoshi Watanabe, Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. E-mail yywata{at}med.osaka-cu.ac.jp

Background and Purpose— Recently, we found that a novel subtype of prostacyclin (PGI2) receptor clearly distinct from the peripheral subtype in terms of ligand specificity is expressed in the central nervous system (CNS). (15R)-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin (15R-TIC) was synthesized and demonstrated to be a specific ligand for this CNS-type PGI2 receptor. Previously, we demonstrated 15R-TIC to be neuroprotective in vivo during transient forebrain ischemia in gerbils and permanent middle cerebral artery occlusion (MCAO) in rats. Furthermore, this compound was shown to exert an anti-apoptotic effect on primary cultured hippocampal neurons, indicating its neuroprotective effect against ischemic insults occurs via direct action on CNS-type PGI2 receptor.

Methods— Local cerebral hemodynamics and oxygen metabolism were measured simultaneously by using positron emission tomography with the 15O steady-state method, before and up to 18 hours after 3-hour transient MCAO reperfusion in cynomolgus monkeys. Methyl ester of 15R-TIC (50 µg/kg, n=4) or its vehicle (10% Intralipos, n=4) was injected intravenously within 5 minutes after onset of MCAO and continuously infused for 5 hours (50 µg/kg per hour).

Results— Neuropathology showed that 15R-TIC significantly reduced cortical damage after 3-hour MCAO. Positron emission tomography results showed 15R-TIC significantly reduced the volume of "infarct" region of interest and attenuated the decrease in cerebral metabolic rate of oxygen and oxygen extraction fraction, and these protective effects were not attributable to improvement of cerebral circulation.

Conclusions— These results suggest that 15R-TIC has a potent neuroprotective effect against focal cerebral ischemia in a monkey MCAO via its direct action on CNS-type PGI2 receptors.


Key Words: cerebral blood flow • cerebral metabolic rate of oxygen • middle cerebral artery occlusion • oxygen extraction fraction • prostacyclin receptor